Ra Medical delays Q1 10-Q filing; cites acquisition accounting issues, goodwill write-off expected

Catheter Precision, Inc.

Company will not file Q1 2023 10-Q by deadline; no exact filing date projected.
Delay due to auditor review of Catheter Precision acquisition accounting, including Series X preferred stock valuation.
Projects Q1 2023 revenue of ~$85,000; expects all or substantially all goodwill to be written off.
Decline in RMED stock price since Jan 9 acquisition date caused decline in value of acquired assets under review.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Catheter Precision, Inc. reported the quarter ended March 31, 2023 results: revenue approximately $85,000.

Period: the quarter ended March 31, 2023
Revenue: approximately $85,000
Result: preliminary results

Exact text from the filing

The Company continues to project revenues for the quarter ended March 31, 2023 of approximately $85,000, and also projects that all or substantially all of its goodwill will be written off as a result of the finalization of the purchase price allocation in connection with the Company’s merger with Catheter Precision, Inc.

View on SEC.gov

Browse all earnings releases →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-007042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.